INT42038

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 26
Total Number 26
Disease Relevance 8.88
Pain Relevance 7.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (ACE) peptidase activity (ACE) extracellular space (ACE)
extracellular region (ACE) plasma membrane (ACE)
Anatomy Link Frequency
coronary artery 2
nasal 2
liver 1
endothelial cells 1
smooth muscle cells 1
ACE (Homo sapiens)
Pain Link Frequency Relevance Heat
bradykinin 144 100.00 Very High Very High Very High
Inflammation 140 100.00 Very High Very High Very High
substance P 69 100.00 Very High Very High Very High
metalloproteinase 69 99.60 Very High Very High Very High
rheumatoid arthritis 122 98.56 Very High Very High Very High
superficial lamina 5 94.16 High High
Enkephalin 17 92.64 High High
Inflammatory response 4 91.92 High High
headache 3 86.88 High High
imagery 41 83.08 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 148 100.00 Very High Very High Very High
Stress 23 100.00 Very High Very High Very High
Hypertension 92 99.80 Very High Very High Very High
Coronary Heart Disease 4 99.34 Very High Very High Very High
Coronary Artery Disease 22 98.96 Very High Very High Very High
Rheumatoid Arthritis 122 98.56 Very High Very High Very High
Cardiovascular Disease 18 97.84 Very High Very High Very High
Nicotine Addiction 3 97.52 Very High Very High Very High
Coagulation Disorder 1 97.32 Very High Very High Very High
Vasculitis 6 96.92 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Topical application of histamine stimulated secretion of ACE activity into nasal lavage fluid (2.90 +/- 0.88 versus 1.53 +/- 0.45 U/liter after saline provocation, P < 0.05 by Bz-Gly-Gly-Gly assay).
Localization (secretion) of ACE in nasal
1) Confidence 0.80 Published 1994 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 8049077 Disease Relevance 0.22 Pain Relevance 0.23
Allergen challenge also induced nasal secretion of ACE.
Localization (secretion) of ACE in nasal
2) Confidence 0.80 Published 1994 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 8049077 Disease Relevance 0.20 Pain Relevance 0.22
HPLC analysis showed that ACE cleaved SP at Phe(8)-Gly(9) and Gly(9)-Leu(10) to release C-terminal tri- and dipeptide (ratio = 4:1).
Localization (release) of ACE associated with substance p
3) Confidence 0.79 Published 2004 Journal Peptides Section Abstract Doc Link 15134871 Disease Relevance 0 Pain Relevance 0.73
ACE released only dipeptide from SP free acid.
Localization (released) of ACE associated with substance p
4) Confidence 0.79 Published 2004 Journal Peptides Section Abstract Doc Link 15134871 Disease Relevance 0 Pain Relevance 0.80
An important difference between ARBs and ACEIs is that, unlike ARBs, ACEIs are predominantly excreted by glomerular filtration.
Localization (excreted) of ACEI
5) Confidence 0.78 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2949902 Disease Relevance 0.56 Pain Relevance 0
The presence of ACE in the human nasal mucosa and in nasal secretions was determined by immunohistochemistry, measures of enzyme activity, and immunoblot.
Localization (secretions) of ACE in nasal mucosa
6) Confidence 0.75 Published 1994 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 8049077 Disease Relevance 0.29 Pain Relevance 0.22
The antiatherogenic ACE-I properties may be related both to the inhibition of tissue and circulating Ang II formation and to bradykinin potentiation, resulting in decreased proliferation and migration of smooth muscle cells, decreased accumulation and activation of inflammatory cells, decreased oxidative stress, and increased endothelial NO formation, leading to improved endothelial function.
Localization (leading) of ACE-I in smooth muscle cells associated with stress, inflammation and bradykinin
7) Confidence 0.74 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663435 Disease Relevance 0.95 Pain Relevance 0.15
T1D and H donors with conditions reported to affect function of angiogenic cells (pregnancy, tumors, peripheral or coronary artery disease, hypertension, habitual smoking, extensive exercise training (e.g. marathon runners), over 55 years of age or taking medication affecting kinin signaling (ACE inhibitors, angiotensin receptor blockers) were excluded from both study groups.
Localization (blockers) of ACE in coronary artery associated with nicotine addiction, coronary artery disease, cancer, diabetes mellitus and hypertension
8) Confidence 0.73 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2887352 Disease Relevance 1.41 Pain Relevance 0.09
Serum rheumatoid factor, plasma viscosity, C-reactive protein, urea and electrolytes, liver function, clotting, auto-immune profile, protein electrophoresis, acetylcholine receptor antibodies, anti-neuronal antibodies, anti-thyroid antibodies, creatine kinase and ACE were all normal.
Localization (creatine kinase) of ACE in liver associated with coagulation disorder
9) Confidence 0.73 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2821394 Disease Relevance 1.05 Pain Relevance 0.62
However, different effects of anesthetic drugs and adjuvants, such as decreased local analgesic effect of the anesthetic ointment EMLA, increased propofol hypnotic effect and paracetamol toxicity, less anti-hypertensive effects of renin-decreasing drugs (ACEI, beta2 blockers and AT1), decreased beta2-vasodilator effects and less t-PA fibrinolysis, may affect pre and postanesthetic approaches, especially in hypertensive, renal, asthma or stroke Afro-American patients.
Localization (decreased) of ACEI
10) Confidence 0.73 Published 2003 Journal Rev Bras Anestesiol Section Body Doc Link 19475293 Disease Relevance 0 Pain Relevance 0
However, different effects of anesthetic drugs and adjuvants, such as decreased local analgesic effect of the anesthetic ointment EMLA, increased propofol hypnotic effect and paracetamol toxicity, less anti-hypertensive effects of renin-decreasing drugs (ACEI, beta2 blockers and AT1), decreased beta2-vasodilator effects and less t-PA fibrinolysis, may affect pre and postanesthetic approaches, especially in hypertensive, renal, asthma or stroke Afro-American patients.
Localization (blockers) of ACEI
11) Confidence 0.73 Published 2003 Journal Rev Bras Anestesiol Section Body Doc Link 19475293 Disease Relevance 0 Pain Relevance 0
Localized on the surface of various cells, ACE is inserted at the cell membrane via its carboxyl terminus.
Localization (Localized) of ACE
12) Confidence 0.71 Published 2003 Journal Curr. Pharm. Des. Section Abstract Doc Link 12570787 Disease Relevance 0 Pain Relevance 0.10
ACE-immunoreactive material was localized by the immunogold technique with silver enhancement to the glycocalyx, between epithelial cells, and to interstitial, extracellular sites in the superficial lamina propria, with the highest intensity of staining immediately beneath the basement membrane.
Localization (localized) of ACE in basement membrane associated with superficial lamina
13) Confidence 0.70 Published 1994 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 8049077 Disease Relevance 0.17 Pain Relevance 0.21
In both histamine and allergen challenges, ACE release correlated closely with that of the vascular proteins IgG and albumin.
Localization (release) of ACE
14) Confidence 0.70 Published 1994 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 8049077 Disease Relevance 0.19 Pain Relevance 0.22
These ACE inhibitory peptides can be enzymatically released from intact proteins in vitro and in vivo during food processing and gastrointestinal digestion, respectively.
Localization (released) of ACE
15) Confidence 0.70 Published 2007 Journal Curr. Pharm. Des. Section Abstract Doc Link 17430180 Disease Relevance 0.08 Pain Relevance 0.22
ACE hydrolyzed NT at Tyr(11)-Ile(12) to release Ile(12)-Leu(13).
Localization (release) of ACE
16) Confidence 0.61 Published 2004 Journal Peptides Section Abstract Doc Link 15134871 Disease Relevance 0 Pain Relevance 0.83
Since the initial application of angiotensin-converting enzyme (ACE) inhibitors as therapeutic agents for the treatment of hypertension, several additional clinical indications have been identified and approved (Brown and Vaughan 1998).
Localization (application) of angiotensin-converting enzyme associated with hypertension
17) Confidence 0.55 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701139 Disease Relevance 0.45 Pain Relevance 0.03
Since the initial application of angiotensin-converting enzyme (ACE) inhibitors as therapeutic agents for the treatment of hypertension, several additional clinical indications have been identified and approved (Brown and Vaughan 1998).
Localization (application) of ACE associated with hypertension
18) Confidence 0.55 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701139 Disease Relevance 0.45 Pain Relevance 0.03
Angiotensin II can be liberated from angiotensin I by ACE or serine proteases.
Localization (liberated) of ACE
19) Confidence 0.55 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701139 Disease Relevance 0.23 Pain Relevance 0
These patients were newly diagnosed with coronary artery disease, some of whom were taking vasoactive drugs such as ACE inhibitors and beta adrenoceptor blockers for hypertension prior to study enrolment.
Localization (blockers) of ACE in coronary artery associated with coronary artery disease and hypertension
20) Confidence 0.51 Published 2008 Journal Atherosclerosis Section Body Doc Link PMC2292239 Disease Relevance 0.25 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox